Cantor Fitzgerald Reiterates “$105.00” Price Target for Spark Therapeutics (ONCE)
“This morning, Spark announced initial plans on U.S. pricing, including a wholesale acquisition cost for LUXTURNA of $425,000/eye ($850,000/ patient).”,” Cantor Fitzgerald’s analyst wrote.
Other equities analysts have also recently issued research reports about the company. Wedbush upgraded Spark Therapeutics from an underperform rating to a neutral rating and decreased their price target for the stock from $65.00 to $50.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Leerink Swann cut Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 price target for the company. in a report on Tuesday, December 12th. BMO Capital Markets set a $89.00 price target on Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, October 10th. Barclays initiated coverage on Spark Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $104.00 price target for the company. Finally, Raymond James Financial reaffirmed a buy rating on shares of Spark Therapeutics in a research report on Tuesday, December 19th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $76.03.
Spark Therapeutics (NASDAQ:ONCE) opened at $50.56 on Wednesday. The firm has a market capitalization of $1,918.36, a P/E ratio of -7.00 and a beta of 3.14. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.07) EPS. analysts forecast that Spark Therapeutics will post -7.58 earnings per share for the current year.
In other Spark Therapeutics news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares of the company’s stock, valued at approximately $876,750. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total value of $416,500.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at $17,909,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,309 shares of company stock worth $4,621,085. 7.30% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of Spark Therapeutics by 11.6% during the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after acquiring an additional 213,520 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Spark Therapeutics by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after acquiring an additional 96,803 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Spark Therapeutics by 46.4% during the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after acquiring an additional 239,723 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in shares of Spark Therapeutics during the 3rd quarter valued at approximately $38,340,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.